Incyte (INCY) Revenue & Revenue Breakdown

Overview ForecastOwnership Financials Chart Transcripts

Incyte Revenue Highlights

Latest Revenue (Y)

$5.14B

Latest Revenue (Q)

$1.37B

Main Segment (Y)

J A K A F I

Main Geography (Y)

U [S]

Incyte Revenue by Period

Incyte Revenue by Year

Date	Revenue	Change
2025-12-31	$5.14B	21.22%
2024-12-31	$4.24B	14.76%
2023-12-31	$3.70B	8.87%
2022-12-31	$3.39B	13.67%
2021-12-31	$2.99B	11.98%
2020-12-31	$2.67B	23.53%
2019-12-31	$2.16B	14.71%
2018-12-31	$1.88B	22.50%
2017-12-31	$1.54B	38.93%
2016-12-31	$1.11B	46.70%
2015-12-31	$753.75M	47.36%
2014-12-31	$511.50M	44.10%
2013-12-31	$354.95M	19.49%
2012-12-31	$297.06M	214.50%
2011-12-31	$94.45M	-44.40%
2010-12-31	$169.88M	1733.55%
2009-12-31	$9.27M	136.41%
2008-12-31	$3.92M	-88.62%
2007-12-31	$34.44M	24.59%
2006-12-31	$27.64M	252.32%
2005-12-31	$7.85M	-44.54%
2004-12-31	$14.15M	-69.96%
2003-12-31	$47.09M	-53.66%
2002-12-31	$101.61M	-53.66%
2001-12-31	$219.26M	12.92%
2000-12-31	$194.17M	23.67%
1999-12-31	$157.00M	16.47%
1998-12-31	$134.80M	52.49%
1997-12-31	$88.40M	111.48%
1996-12-31	$41.80M	242.62%
1995-12-31	$12.20M	6000.00%
1994-12-31	$200.00K	-33.33%
1993-12-31	$300.00K	-

Incyte generated $5.14B in revenue during NA 2025, up 21.22% compared to the previous quarter, and up 192.79% compared to the same period a year ago.

Incyte Revenue by Quarter

Date	Revenue	Change
2025-09-30	$1.37B	12.38%
2025-06-30	$1.22B	15.45%
2025-03-31	$1.05B	-10.67%
2024-12-31	$1.18B	3.59%
2024-09-30	$1.14B	9.02%
2024-06-30	$1.04B	18.49%
2024-03-31	$880.89M	-13.07%
2023-12-31	$1.01B	10.26%
2023-09-30	$919.02M	-3.73%
2023-06-30	$954.61M	18.05%
2023-03-31	$808.67M	-12.74%
2022-12-31	$926.70M	12.56%
2022-09-30	$823.30M	-9.67%
2022-06-30	$911.40M	24.30%
2022-03-31	$733.24M	-15.02%
2021-12-31	$862.85M	6.13%
2021-09-30	$812.99M	15.20%
2021-06-30	$705.71M	16.70%
2021-03-31	$604.72M	-23.41%
2020-12-31	$789.51M	27.21%
2020-09-30	$620.64M	-9.80%
2020-06-30	$688.04M	21.03%
2020-03-31	$568.51M	-1.88%
2019-12-31	$579.39M	5.04%
2019-09-30	$551.58M	4.09%
2019-06-30	$529.93M	6.44%
2019-03-31	$497.86M	-5.78%
2018-12-31	$528.40M	17.51%
2018-09-30	$449.68M	-13.77%
2018-06-30	$521.52M	36.42%
2018-03-31	$382.28M	-13.93%
2017-12-31	$444.16M	16.41%
2017-09-30	$381.53M	16.88%
2017-06-30	$326.44M	-15.01%
2017-03-31	$384.08M	17.64%
2016-12-31	$326.50M	21.16%
2016-09-30	$269.47M	9.41%
2016-06-30	$246.29M	-6.52%
2016-03-31	$263.46M	8.03%
2015-12-31	$243.88M	29.99%
2015-09-30	$187.61M	15.11%
2015-06-30	$162.98M	2.33%
2015-03-31	$159.28M	28.48%
2014-12-31	$123.97M	-37.43%
2014-09-30	$198.15M	98.98%
2014-06-30	$99.58M	10.90%
2014-03-31	$89.79M	-7.50%
2013-12-31	$97.07M	14.04%
2013-09-30	$85.12M	-16.28%
2013-06-30	$101.67M	43.05%
2013-03-31	$71.08M	-37.57%
2012-12-31	$113.85M	88.20%
2012-09-30	$60.49M	-30.10%
2012-06-30	$86.54M	139.21%
2012-03-31	$36.18M	25.23%
2011-12-31	$28.89M	72.15%
2011-09-30	$16.78M	-0.17%
2011-06-30	$16.81M	-47.42%
2011-03-31	$31.97M	-62.77%
2010-12-31	$85.87M	408.95%
2010-09-30	$16.87M	-66.15%
2010-06-30	$49.85M	188.33%
2010-03-31	$17.29M	151.79%
2009-12-31	$6.87M	631.20%
2009-09-30	$939.00K	19.01%
2009-06-30	$789.00K	17.59%
2009-03-31	$671.00K	-28.46%
2008-12-31	$938.00K	-11.59%
2008-09-30	$1.06M	72.80%
2008-06-30	$614.00K	-53.02%
2008-03-31	$1.31M	-

Incyte generated $1.37B in revenue during Q3 2025, up 12.38% compared to the previous quarter, and up 130.87% compared to the same period a year ago.

Incyte Revenue Breakdown

Incyte Revenue Breakdown by Product

Annual Revenue by Product

Product/Service	Dec 25	Dec 24	Dec 22	Dec 21	Dec 20
OPZELURA	$678.46M	$508.29M	$128.74M	$4.91M	-
I C L U S I G	$134.07M	$114.32M	$105.84M	$105.00M	-
J A K A F I	$3.55B	$3.21B	$2.74B	-	-
M I N J U V I	$144.58M	$119.24M	$19.65M	-	-
Milestone And Contract Revenue	$150.00M	$43.00M	$165.00M	$205.00M	-
Olumiant Royalty	$144.60M	$135.57M	$134.55M	$110.92M	-
ZYNYZ	$66.35M	$3.19M	-	-	-
PEMAZYRE Royalty Revenues	$86.73M	$83.92M	$84.65M	-	-
Tabrecta Royalty Revenues	$26.70M	$22.75M	$15.41M	$4.14M	-
Royalty	-	-	$482.74M	$392.97M	-
Product	-	-	$2.75B	$2.07B	-
Milestone and contract revenues	-	-	$165.00M	$95.00M	-
ICLUSIG	-	-	-	$4.67M	-
JAKAVI Royalty Revenues	-	-	-	$337.99M	-
MINJUVI	-	-	-	$68.53M	-
OLUMIANT Royalty Revenues	-	-	-	$220.88M	-
PEMAZYRE	-	-	-	$109.39M	-
Product revenues, net	-	-	-	$2.32B	-
Product royalty revenues	-	-	-	$569.25M	-
TABRECTA Royalty Revenues	-	-	-	$10.39M	-
Pemazyre	-	-	-	-	$25.88M
Jakavi Royalty Revenues	-	-	-	-	$277.90M

Incyte's latest annual revenue breakdown by segment (product or service), as of Dec 25: J A K A F I (71.27%), OPZELURA (13.62%), Milestone And Contract Revenue (3.01%), Olumiant Royalty (2.90%), M I N J U V I (2.90%), I C L U S I G (2.69%), PEMAZYRE Royalty Revenues (1.74%), ZYNYZ (1.33%), and Tabrecta Royalty Revenues (0.54%).

Quarterly Revenue by Product

Product/Service	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20
ZYNYZ	$31.75M	$22.67M	$8.92M	$3.01M	$1.37M	$694.00K	$651.00K	$467.00K	-	-	-	-	-	-	-	-	-	-	-	-
PEMAZYRE Royalty Revenues	$23.35M	$22.74M	$22.19M	$18.44M	$23.48M	$21.07M	$21.14M	$18.22M	-	-	-	-	-	-	-	-	-	-	-	-
OPZELURA	$207.28M	$187.97M	$164.50M	$118.70M	$161.60M	$139.27M	$121.69M	$85.72M	$91.84M	$80.23M	$56.55M	$38.14M	$16.56M	$12.75M	-	-	-	-	-	-
Olumiant Royalty	$43.21M	$37.11M	$33.48M	$30.80M	$38.48M	$34.80M	$31.70M	$30.59M	$86.57M	$36.05M	$32.26M	$31.00M	-	-	-	-	-	-	-	-
I C L U S I G	$34.22M	$37.58M	$32.73M	$29.54M	$27.37M	$29.75M	$26.86M	$30.34M	$28.52M	$28.19M	$25.64M	$28.58M	-	-	-	-	-	-	-	-
J A K A F I	$958.47M	$916.72M	$873.50M	$801.56M	$2.91B	$115.74M	$99.32M	$89.59M	$547.37M	$529.05M	$465.71M	$516.88M	-	-	-	-	-	-	-	-
M I N J U V I	$41.91M	$41.99M	$31.13M	$29.55M	$32.81M	$31.44M	$31.12M	$23.87M	$556.00K	-	-	-	-	-	-	-	-	-	-	-
Milestone And Contract Revenue	$100.00M	$45.00M	$5.00M	-	$18.00M	-	$25.00M	$35.00M	$10.00M	$110.00M	-	-	-	-	-	-	-	-	-	-
Tabrecta Royalty Revenues	$7.14M	$6.51M	$6.63M	$6.41M	$6.29M	$5.93M	$5.30M	$5.23M	$2.75M	$2.48M	$2.05M	$2.00M	-	-	-	-	-	-	-	-
ICLUSIG	-	-	-	-	-	-	-	$30.34M	$27.72M	$29.09M	$27.68M	$25.93M	$26.22M	$26.07M	$-77.69M	-	-	-	-	-
JAKAVI Royalty Revenues	-	-	-	-	-	-	-	$89.59M	$96.55M	$90.45M	$76.69M	$85.81M	$83.71M	$70.87M	$95.70M	-	-	-	-	-
Milestone and contract revenues	-	-	-	-	-	-	-	$25.00M	-	$5.00M	$50.00M	-	-	-	-	-	-	-	-	-
OLUMIANT Royalty Revenues	-	-	-	-	-	-	-	$30.59M	$29.61M	$32.01M	$34.16M	$20.37M	$66.00M	-	-	-	-	-	-	-
PEMAZYRE	-	-	-	-	-	-	-	$17.68M	$18.94M	$21.57M	$22.48M	$23.41M	$18.98M	$18.03M	$60.47M	-	-	-	-	-
Product	-	-	-	-	-	-	-	$729.92M	$783.20M	$827.00M	$693.24M	$713.01M	$594.01M	$575.15M	$504.81M	$559.47M	-	-	-	-
Royalty	-	-	-	-	-	-	-	$125.97M	$130.83M	$127.61M	$115.44M	$110.29M	$183.97M	$120.56M	$99.91M	$120.04M	-	-	-	-
TABRECTA Royalty Revenues	-	-	-	-	-	-	-	$5.23M	$4.14M	$4.80M	$4.18M	$4.11M	$3.58M	$3.48M	$3.12M	-	-	-	-	-
MINJUVI	-	-	-	-	-	-	-	-	$8.35M	$13.16M	$6.56M	$5.93M	$4.41M	$4.50M	$67.97M	-	-	-	-	-
JAKAFI	-	-	-	-	-	-	-	-	$636.25M	$682.38M	$579.97M	$647.49M	$619.60M	$597.67M	$544.46M	$592.37M	-	-	-	-
Product royalty revenues	-	-	-	-	-	-	-	-	-	-	-	-	-	$117.55M	$122.41M	$164.81M	-	-	-	-
Product revenues, net	-	-	-	-	-	-	-	-	-	-	-	-	-	$663.85M	$605.82M	$648.04M	-	-	-	-
Jakavi Royalty Revenues	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$94.66M	$82.04M	$65.60M	$87.05M
Pemazyre	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$17.56M	$17.91M	$13.46M	$14.01M

Incyte's latest quarterly revenue breakdown by segment (product or service), as of Dec 25: J A K A F I (66.22%), OPZELURA (14.32%), Milestone And Contract Revenue (6.91%), Olumiant Royalty (2.99%), M I N J U V I (2.90%), I C L U S I G (2.36%), ZYNYZ (2.19%), PEMAZYRE Royalty Revenues (1.61%), and Tabrecta Royalty Revenues (0.49%).

Incyte Revenue Breakdown by Country

Annual Revenue by Country

Country	Dec 25	Dec 24	Dec 22	Dec 21	Dec 20
U [S]	$4.80B	$4.00B	-	-	-
Europe	$323.73M	$260.40M	$147.00M	$124.10M	$105.00M
UNITED STATES	-	-	$3.20B	-	-
U.S.	-	-	-	$2.90B	-
U	-	-	-	-	$2.60B

Incyte's latest annual revenue breakdown by geography, as of Dec 25: U [S] (93.68%), and Europe (6.32%).

Quarterly Revenue by Country

Country	Dec 25	Sep 25	Jun 25	Mar 25	Dec 19	Dec 18
U [S]	$1.42B	$1.26B	$1.13B	$981.60M	-	-
Europe	$76.00M	$100.31M	$78.83M	$68.60M	-	-
Non Us	-	-	-	-	$88.60M	$69.20M

Incyte's latest quarterly revenue breakdown by geography, as of Dec 25: U [S] (94.94%), and Europe (5.06%).

Incyte Peer Comparison by Revenue

Ticker	Company	Last Year Revenue	Last Quarter Revenue
THC	Tenet Healthcare	$21.31B	$5.29B
GMAB	Genmab	$16.47B	$4.14B
DGX	Quest Diagnostics	$11.04B	$2.82B
BIIB	Biogen	$9.81B	$2.53B
ZBH	Zimmer Biomet	$8.23B	$2.00B
INCY	Incyte	$5.14B	$1.37B
ILMN	Illumina	$4.34B	$1.08B
UTHR	United Therapeutics	$3.18B	$799.50M
WAT	Waters	$3.17B	$799.89M
WST	West Pharmaceutical Services	$3.07B	$804.70M
RPRX	Royalty Pharma	$2.38B	$609.29M

INCY Revenue FAQ

What is Incyte’s yearly revenue?

Incyte's yearly revenue for 2025 was $5.14B, representing an increase of 21.22% compared to 2024. The company's yearly revenue for 2024 was $4.24B, representing an increase of 14.76% compared to 2023. INCY's yearly revenue for 2023 was $3.7B, representing an increase of 8.87% compared to 2022.

What is Incyte’s quarterly revenue?

Incyte's quarterly revenue for Q3 2025 was $1.37B, a 12.38% increase from the previous quarter (Q2 2025), and a 20.05% increase year-over-year (Q3 2024). The company's quarterly revenue for Q2 2025 was $1.22B, a 15.45% increase from the previous quarter (Q1 2025), and a 16.46% increase year-over-year (Q2 2024). INCY's quarterly revenue for Q1 2025 was $1.05B, a -10.67% decrease from the previous quarter (Q4 2024), and a 19.53% increase year-over-year (Q1 2024).

What is Incyte’s revenue growth rate?

Incyte's revenue growth rate for the last 3 years (2023-2025) was 39.12%, and for the last 5 years (2021-2025) was 72.16%.

What are Incyte’s revenue streams?

Incyte's revenue streams in c 25 are OPZELURA, I C L U S I G, J A K A F I, M I N J U V I, Milestone And Contract Revenue, Olumiant Royalty, ZYNYZ, PEMAZYRE Royalty Revenues, and Tabrecta Royalty Revenues. OPZELURA generated $678.46M in revenue, accounting 13.62% of the company's total revenue, up 33.48% year-over-year. I C L U S I G generated $134.07M in revenue, accounting 2.69% of the company's total revenue, up 17.28% year-over-year. J A K A F I generated $3.55B in revenue, accounting 71.27% of the company's total revenue, up 10.57% year-over-year. M I N J U V I generated $144.58M in revenue, accounting 2.90% of the company's total revenue, up 21.25% year-over-year. Milestone And Contract Revenue generated $150M in revenue, accounting 3.01% of the company's total revenue, up 248.84% year-over-year. Olumiant Royalty generated $144.6M in revenue, accounting 2.90% of the company's total revenue, up 6.66% year-over-year. ZYNYZ generated $66.35M in revenue, accounting 1.33% of the company's total revenue, up 1983.23% year-over-year. PEMAZYRE Royalty Revenues generated $86.73M in revenue, accounting 1.74% of the company's total revenue, up 3.35% year-over-year. Tabrecta Royalty Revenues generated $26.7M in revenue, accounting 0.54% of the company's total revenue, up 17.39% year-over-year.

What is Incyte’s main source of revenue?

For the fiscal year ending Dec 25, the largest source of revenue of Incyte was J A K A F I. This segment made a revenue of $3.55B, representing 71.27% of the company's total revenue.